구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials | |||
|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication | Anti-TNF |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb | Abu Dhabi Stem Cells Center |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | Polyarticular Course Juvenile Idiopathic | Dementia |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Rheumatoid Arthritis |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | — | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | — | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Targeting specific cytokine pathway | Targeting viral protein‑host signaling |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Half-life | ~14–19 days (SC) | 30 h | — | 248.54 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores | Mouse, Rat, Human | Mouse |
PK/PD Animal (cat.) | Rat | Rat, In vitro | Human, Mouse, Rat, In vitro | Mouse |
PK/PD Experiment | pd | pharmacokinetic | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat | Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | NHP | — | Human, Mouse, Rat, In vitro | Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Toxicology CRS | N/A | N/A | — | grade 3 |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Selected reported efficacy | — | 73.4% | 27.5% | — |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | — | — |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 | ClinicalTrials.gov NCT02015520 | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 | NCT02015520 | — |
Preclinical Animal (cat.) | — | Rat | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials | |||
|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication | Anti-TNF |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb | Abu Dhabi Stem Cells Center |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | Polyarticular Course Juvenile Idiopathic | Dementia |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Rheumatoid Arthritis |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | — | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | — | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Targeting specific cytokine pathway | Targeting viral protein‑host signaling |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Half-life | ~14–19 days (SC) | 30 h | — | 248.54 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores | Mouse, Rat, Human | Mouse |
PK/PD Animal (cat.) | Rat | Rat, In vitro | Human, Mouse, Rat, In vitro | Mouse |
PK/PD Experiment | pd | pharmacokinetic | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat | Mouse, Rat, Human | Mouse |
Toxicology Animal (cat.) | NHP | — | Human, Mouse, Rat, In vitro | Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Toxicology CRS | N/A | N/A | — | grade 3 |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors.. Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic … | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Selected reported efficacy | — | 73.4% | 27.5% | — |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | — | — |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 | ClinicalTrials.gov NCT02015520 | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 | NCT02015520 | — |
Preclinical Animal (cat.) | — | Rat | — | — |
추천 비교
추천 비교